The global parenteral nutrition market size was valued at USD 5.3 billion in 2018 and is expected to exhibit a CAGR of 5.8% over the forecast period. Presence of a large number of malnourished children, high natality rate around the globe, increasing premature births, rising occurrence of cancer, which requires administration of vital nutrients to increase hydration, energy, and strength of cancer patients, and rising adoption by healthcare settings for the administration of nutrients in chronically ill geriatric patients are driving the market.
Malnutrition is one of the major drivers in the parenteral nutrition market. As per the UNICEF, poor nutrition to infants in their initial 1,000 days may lead to impaired cognitive ability and stunted growth. An infant’s diet must contain a proper balance of vitamins, minerals, amino acids, starch, and lipids. These vital nutrients can be administered via parenteral nutrition, which is estimated to propel the market growth.
Furthermore, the American Society for Parenteral and Enteral Nutrition (ASPEN) recognized the increasing risk of malnourishment in about 30-50% of hospitalized patients leading to increasing costs and readmission rates. To educate and raise awareness among patients and healthcare providers, the institute launched the malnutrition awareness week.
Individuals and healthcare authorities are paying extensive focus on limiting the mortality rate due to early birth and are thereby propelling the use of parenteral nutrition. The premature birth rate of the U.S. is around 9.6%, as of 2016, and the national authorities are working to decrease it to 8.1% as stated by the National Center for Healthcare Statistics. Hence, a large number of neonates requiring supplementary nutrition post-birth is expected to boost the market demand over the forecast period.
According to the World Health Organization (WHO), around 14.0 billion new cases of mortality due to cancer were accounted for in 2014. The organization also stated that about 70.0% increase in cancer diagnosis may be expected by 2025, which is anticipated to fuel the market growth. Hence, the market is anticipated to be driven by an increasing population base of cancer-induced anemia patients.
Increasing occurrence of chronic conditions, such as cancer, influences the usage of parenteral nutrition around the globe. The benefit of parenteral nutrition is that it helps in the administration of vital nutrients that help in maintaining the hydration level, energy, and strength in cancer patients, therefore acting as a vital impact rendering driver anticipated to surge market growth throughout the forecast period.
Single-dose amino acid solutions held a substantial share in 2018. Increased use of amino acid solutions can be credited to an increase in the influx of regulatory approved solutions. Besides, newly available solutions of amino acid possess fewer side effects, thus enhancing patient benefits.
Parenteral lipid emulsion has potential benefits as a drug delivery vehicle due to which it is expected to witness the highest growth. It is mainly used for the administration of drugs that prevent thrombophlebitis and reduce irritation and pain. Lipid emulsions are also prescribed for pediatric patients as they are a non-carbohydrate source of energy in low osmolarity and volume. These lipid emulsions are also useful in maintaining net nitrogen balance in parenteral nutrition solutions. Moreover, these are a rich source of essential fatty acids.
North America dominated the overall market in 2018, owing to the presence of high research expenditure by government agencies and private entities in the healthcare sector, technologically advanced medical devices, and collaborations among regulatory authorities, the medical device industry, and universities. Moreover, rising occurrence of several chronic diseases, the existence of advanced healthcare facilities, as well as favorable reimbursement policies have led to an increase in hospital admission that is anticipated to boost the usage rates in this region.
Asia-Pacific is projected to witness lucrative growth throughout the forecast period. Economic development in nations such as China, India, and Japan, along with favorable government initiatives related to the development of healthcare infrastructure and reimbursement policies, is further anticipated to fuel market growth. Besides, growing Foreign Direct Investment (FDI) in the medical devices and healthcare sectors by various private and government organizations are expected to provide incentives for manufacturing technologically-advanced products over the forecast period.
Some of the key market players operating in the industry are Baxter International Inc.; Grifols International S.A.; Actavis Inc.; B. Braun Melsungen AG; Fresenius Kabi AG; and Hospira Inc. These companies are actively involved in improving the current product portfolio of parenteral nutrition to sustain their position in the market. Moreover, the development of new drugs and their entry in the untapped regions are estimated to boost the market growth. For instance, in 2016, Baxter International received marketing authorization for its product NUMETA G13E from the competent authorities in U.K. and Denmark.
Attribute |
Details |
Base year for estimation |
2018 |
Actual estimates/Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Market representation |
Revenue in USD Million and CAGR from 2019 to 2026 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, U.K., Germany, Spain, Italy, France, Japan, China, India, Thailand, South Korea, Brazil, Mexico, Argentina, Colombia, South Africa, Saudi Arabia, UAE |
Report coverage |
Revenue forecast, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research, Inc. has segmented the global parenteral nutrition market report on the basis of nutrient type and region:
Nutrient Type Outlook (Revenue, USD Million, 2015 - 2026)
Carbohydrates
Lipid Emulsion
Single Dose Amino Acid Solution
Trace Elements
Vitamins & Minerals
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
The U.S.
Canada
Europe
U.K.
Germany
Spain
Italy
France
Asia Pacific
Japan
China
India
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.